These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8275623)

  • 1. Trial of oral physostigmine in amyotrophic lateral sclerosis.
    Norris FH; Tan Y; Fallat RJ; Elias L
    Clin Pharmacol Ther; 1993 Dec; 54(6):680-2. PubMed ID: 8275623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A controlled study of physostigmine versus neostigmine.
    Aquilonius SM; Askmark H; Eckernäs SA; Gillberg PG; Hilton-Brown P; Rydin E; Stålberg E
    Acta Neurol Scand; 1986 Jun; 73(6):628-32. PubMed ID: 3529799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group.
    Miller RG; Moore D; Young LA; Armon C; Barohn RJ; Bromberg MB; Bryan WW; Gelinas DF; Mendoza MC; Neville HE; Parry GJ; Petajan JH; Ravits JM; Ringel SP; Ross MA
    Neurology; 1996 Dec; 47(6):1383-8. PubMed ID: 8960715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.
    Cudkowicz ME; Shefner JM; Schoenfeld DA; Brown RH; Johnson H; Qureshi M; Jacobs M; Rothstein JD; Appel SH; Pascuzzi RM; Heiman-Patterson TD; Donofrio PD; David WS; Russell JA; Tandan R; Pioro EP; Felice KJ; Rosenfeld J; Mandler RN; Sachs GM; Bradley WG; Raynor EM; Baquis GD; Belsh JM; Novella S; Goldstein J; Hulihan J;
    Neurology; 2003 Aug; 61(4):456-64. PubMed ID: 12939417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we eliminate placebo in ALS clinical trials?
    Bryan WW; Hoagland RJ; Murphy J; Armon C; Barohn RJ; Goodpasture JC; Miller RG; Parry GJ; Petajan JH; Ross MA; Stromatt SC;
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Apr; 4(1):11-5. PubMed ID: 12745612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis.
    Lacomblez L; Bouche P; Bensimon G; Meininger V
    Neurology; 1989 Dec; 39(12):1635-7. PubMed ID: 2685660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.
    Miller RG; Petajan JH; Bryan WW; Armon C; Barohn RJ; Goodpasture JC; Hoagland RJ; Parry GJ; Ross MA; Stromatt SC
    Ann Neurol; 1996 Feb; 39(2):256-60. PubMed ID: 8967757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis.
    Shefner JM; Wolff AA; Meng L; Bian A; Lee J; Barragan D; Andrews JA;
    Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(5-6):426-435. PubMed ID: 26982815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
    Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
    Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial of celecoxib in amyotrophic lateral sclerosis.
    Cudkowicz ME; Shefner JM; Schoenfeld DA; Zhang H; Andreasson KI; Rothstein JD; Drachman DB
    Ann Neurol; 2006 Jul; 60(1):22-31. PubMed ID: 16802291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group.
    Neurology; 1996 May; 46(5):1244-9. PubMed ID: 8628460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock: study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se).
    Zimmermann JB; Pinder N; Bruckner T; Lehmann M; Motsch J; Brenner T; Hoppe-Tichy T; Swoboda S; Weigand MA; Hofer S
    Trials; 2017 Nov; 18(1):530. PubMed ID: 29126416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis.
    Lange DJ; Murphy PL; Diamond B; Appel V; Lai EC; Younger DS; Appel SH
    Arch Neurol; 1998 Jan; 55(1):93-6. PubMed ID: 9443715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
    Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
    Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled trial of nimodipine in amyotrophic lateral sclerosis.
    Miller RG; Shepherd R; Dao H; Khramstov A; Mendoza M; Graves J; Smith S
    Neuromuscul Disord; 1996 Mar; 6(2):101-4. PubMed ID: 8664560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics.
    Andrews JA; Cudkowicz ME; Hardiman O; Meng L; Bian A; Lee J; Wolff AA; Malik FI; Shefner JM
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):259-266. PubMed ID: 29402141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized sequential trial of creatine in amyotrophic lateral sclerosis.
    Groeneveld GJ; Veldink JH; van der Tweel I; Kalmijn S; Beijer C; de Visser M; Wokke JH; Franssen H; van den Berg LH
    Ann Neurol; 2003 Apr; 53(4):437-45. PubMed ID: 12666111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data.
    Tandan R; Bromberg MB; Forshew D; Fries TJ; Badger GJ; Carpenter J; Krusinski PB; Betts EF; Arciero K; Nau K
    Neurology; 1996 Nov; 47(5):1220-6. PubMed ID: 8909433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.